(Q34558346)

English

A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

0 references

1 reference

Europe PubMed Central

A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity (English)

1 reference

Europe PubMed Central

3 August 2017

1 reference

based on heuristic

inferred from title

author name string

van de Kerkhof PC

1

1 reference

Europe PubMed Central

3 August 2017

Wasel N

2

1 reference

Europe PubMed Central

3 August 2017

Kragballe K

3

1 reference

Europe PubMed Central

3 August 2017

Cambazard F

4

1 reference

Europe PubMed Central

3 August 2017

Murray S

5

1 reference

Europe PubMed Central

3 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2005

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

210

1 reference

Europe PubMed Central

3 August 2017

4

1 reference

Europe PubMed Central

3 August 2017

294-299

1 reference

Europe PubMed Central

3 August 2017

Quality of life measurement in dermatology: a practical guide

1 reference

https://api.crossref.org/works/10.1159%2F000084753

21 January 2018

Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1159%2F000084753

21 January 2018

A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1159%2F000084753

21 January 2018

A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1159%2F000084753

21 January 2018

Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical tria

1 reference

https://api.crossref.org/works/10.1159%2F000084753

21 January 2018

Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1159%2F000084753

21 January 2018

Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1159%2F000084753

21 January 2018

The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment

1 reference

https://api.crossref.org/works/10.1159%2F000084753

21 January 2018

Identifiers

10.1159/000084753

1 reference

Europe PubMed Central

3 August 2017

release_aeuryytpgner7n54m3cjerjlbu

1 reference

https://api.fatcat.wiki/v0/release/aeuryytpgner7n54m3cjerjlbu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34558346&oldid=1976098576"